It is unknown whether imatinib prior to myeloablative haematopoietic stem cell transplantation (HSCT) increases transplant-related toxicity. Among the side effects induced by imatinib, myelosuppression and liver injury might worsen HSCT outcomes. We retrospectively analysed engraftment, liver toxicity, acute graft-versushost disease (aGVHD) incidence and 100-day mortality in 30 patients with BCR/ABL-positive leukaemias who received imatinib before HSCT and compared results of 48 age-matched controls who did not receive preceding imatinib. Both neutrophil and platelet engraftment occurred more rapidly among imatinib patients but the differences adjusted for Gratwohl scale were not statistically significant (P ¼ 0.18 and 0.22, respectively). The adjusted hazards of having liver function tests (LFTs) 41.5 normal increased and the adjusted durations of elevated LFTs were not significantly different. The estimated adjusted difference in mean peak bilirubin values was also not significantly different (P ¼ 0.48). However, the adjusted hazard of increased creatinine 41.5 normal was significantly higher in the imatinib group (HR ¼ 4.09, P ¼ 0.02). The adjusted odds of grades II-IV aGVHD were similar in both groups (OR ¼ 0.86, P ¼ 0.78), and while the adjusted odds of 100-day mortality were lower among imatinib patients, the difference was not significant (OR ¼ 0.65, P ¼ 0.60). These data do not provide any evidence that imatinib preceding HSCT increases acute transplant-related toxicities.
There is general agreement that allogeneic haematopoietic stem cell transplantation (HSCT) has the potential to cure selected patients with BCR-ABL-positive chronic myeloid leukaemia (CML), due to the graft-versus-leukaemia effect of donor cells. However, conventional HSCT is associated with substantial risk for severe complications or death, and the survival advantage of transplant recipients compared to patients treated with nontransplantation methods may therefore not be seen before 4-5 years following transplant.
1,2 Introduction of imatinib mesylate, a potent inhibitor of the BCR-ABL protein tyrosine kinase, suggests that HSCT may not be indispensable to achieve a cure. 3 Indeed, in chronic phase imatinib has been reported to induce a major cytogenetic response in nearly 90% of patients 4 which, based on interferon-alfa (INF-a) experience, has been accepted as a surrogate marker for longer survival in CML. Although the durability of response to imatinib and whether the benefit derived from cytogenetic response to INF-a can be extrapolated to imatinib are not known, the number of HSCT performed for newly diagnosed CML patients has decreased more than 30% over the last 3 years in Europe 5 and the USA. 6 Nonetheless, there are some patients who either have upfront resistance to imatinib or develop resistance during treatment. 7 Imatinib resistance is generally accepted as an indication for HSCT, since survival of these patients is rather short. 8 A brief response to imatinib is also seen in patients with advanced phase of CML or BCR-ABLpositive acute lymphoblastic leukaemia (ALL), 9 ,10 although imatinib enables some patients, resistant to standard chemotherapy, to achieve a response, thus making them eligible for allogeneic HSCT. 11, 12 One may expect, therefore, the number of patients receiving allogeneic HSCT after imatinib treatment to increase in the near future.
Imatinib has been well tolerated in clinical trials. 13 However, the effect on clinical outcome of imatinib therapy immediately preceding a myeloablative HSCT is unknown. Among the side effects of imatinib use thus far reported, at least two might be clinically relevant for stem cell transplantation: myelosuppression and liver toxicity. 13, 14 Stable donor engraftment is obviously critical for survival among patients who have received a myeloablative conditioning regimen, whereas liver complications remain a major source of mortality and morbidity in such patients. 15 In the present study, we retrospectively analysed acute transplant-related toxicity among patients who received imatinib and among age-matched patients who did not receive imatinib prior to myeloablative HSCT. Specifically we compared time to neutrophil and platelet engraftment, the occurrence of liver toxicity including incidence of sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), the incidence and severity of acute graft-versus-host disease (aGVHD), and the probability of day-100 mortality.
Patients, materials and methods

Patients and disease characteristics
Between November 2001 and September 2003, 30 patients at the Medical University of Gdan´sk, Poland (PL), Silesian Medical University in Katowice, PL and Medical University of Wroc"aw, PL received HSCT from human leukocyte antigen-matched related (n ¼ 8) and unrelated (n ¼ 22) donors after myeloablative conditioning for treatment of Ph-positive CML (n ¼ 26) and ALL (n ¼ 4) following the use of imatinib. Medical records were reviewed under protocols approved by the local Review Boards. Written informed consent was obtained from all patients before transplantation. The indication for use of imatinib (Glivec, Novartis, Warsaw, PL) in patients with CML was advanced phase of the disease (n ¼ 19, 63%), INF-a resistance (n ¼ 10, 33%), and in one adolescent patient imatinib was used as a first-line treatment. Three patients with ALL received imatinib for early disease relapse after induction chemotherapy, and one ALL patient with primary chemorefractory disease received imatinib as a third-line induction treatment. The median time of imatinib administration before HSCT was 210 (5-772) days. In all, 13 patients received imatinib for less than 200 days. A total of 15 patients were given imatinib at a dose of 400 mg/day and the remaining 15 received a dose of 600 mg/day. Eight patients who received the higher dose of imatinib were given the drug for more than 200 days. Imatinib was stopped at a median of 13 (1-119) days before the day of cell infusion (day 0). Two patients received imatinib during conditioning. For each CML patient, Gratwohl scale was used to assess the risk for transplantrelated mortality. 16 Control patients (n ¼ 48) were chosen from the same centre at which a corresponding imatinib patient was transplanted, and the controls were agematched with the imatinib patients. Initially an attempt was made to also match for Gratwohl scale, but it quickly became apparent that such matches did not exist for every imatinib patient. A maximum of two age-matched controls were chosen for each imatinib patient, this number limited due to the fact that substantial chart review was necessary for all patients analysed.
Transplantation characteristics
Of 30 imatinib patients, 22 (73%) were conditioned with non-TBI-based regimens (Table 1) . CML patients transplanted from family donors were conditioned with busulfan (4 mg/kg p.o. per day in divided doses for 4 consecutive days) and cyclophosphamide (60 mg/kg once daily i.v. for 2 consecutive days) (Bu 16 Cy 120 ). 17 The same regimen together with rabbit antithymocyte globulin (ATG) was used for 10 CML-unrelated recipients. Busulfan levels were not targeted. Five other unrelated patients received fractionated TBI (12 Gy) with Cy 120 and ATG, and four received a myeloablative dose of treosulfan and fludarabine (Flu) combined with ATG. 18 TBI with Cy 120 was used for all patients with ALL. Unrelated ALL recipients additionally received ATG. A standard therapy of methotrexate plus cyclosporine was used for GVHD prophylaxis as previously described. 19 Engraftment and acute GVHD Time to neutrophil engraftment was defined as the first of 3 consecutive days in which the absolute neutrophil count (ANC) exceeded 500/ml. Time to platelet engraftment was defined as the first of 3 consecutive days in which the platelet count exceeded 50 000/ml. The peak severity of aGVHD was graded by one investigator at each centre according to previously published criteria. 20 
Assessment of liver and kidney function
Before transplantation, all patients were routinely screened for the presence of liver disease by history, physical examination, and laboratory liver function tests (LFTs) (serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase (FALK) and tests for hepatitis viruses). After transplantation, LFTs were performed at least three times a week or as clinically indicated. Patients with symptoms or LFT abnormalities were evaluated by additional laboratory tests and liver imaging. Liver injury after transplantation was assessed by calculating for each LFT the total number of days with levels elevated 41.5 times the upper normal limit within the first 100 days after transplantation, the time to the first such increase for at least 3 consecutive days, and the peak value. A clinical diagnosis and severity of SOS (mild, moderate and severe) was made according to published criteria. 21 Impairment of renal function after transplantation was documented by the number of days with elevated creatinine 41.5 the normal upper limit within the first 100 days, the time to the first such increase for 3 consecutive days, and the peak creatinine value. Liver and kidney toxicity was also graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (Version 2.0).
Statistical analysis
Linear regression was used to compare time to engraftment among patients who achieved the appropriate engraftment end point. Linear regression was also used to compare the duration of elevated lab values. For each of these outcomes, the regression models were adjusted for Gratwohl scale. Since the Gratwohl scale is applicable only to CML patients, the eight ALL patients were arbitrarily assigned a Gratwohl scale of 2.87, this being the mean value of the CML patients. The models for duration of elevated values were additionally adjusted for the number of days survived within the first 100 days post transplant. Cox regression was used to compare the hazard of achieving a lab value 1.5 times the normal upper limit, with time to the first such occurrence serving as the time of failure. Patients who did not achieve such a value were censored at the earliest of death or day 100. These models were also adjusted for Gratwohl scale. Logistic regression was used to compare the odds of aGVHD and the odds of day-100 mortality, with adjustment for Gratwohl scale. The impact of duration of imatinib treatment on outcome was assessed by assigning a duration of zero days to the nonimatinib patients and categorizing duration for the imatinib patients as 1-200 days or 4200 days. All P-values from regression models were estimated from the Wald test and are two-sided. No adjustments were made for multiple comparisons.
Results
Pretransplant characteristics
Median patient age was similar in the two groups. There was no statistically significant difference in the number of patients receiving INF-a within 90 days before HSCT between imatinib and non-imatinib patients (Table 1) . Unrelated donors were used more often for imatinibtreated patients (73%) than non-imatinib controls (50%), but the difference was not statistically significant. There was no statistically significant difference in the source of stem cells between the two groups of patients. Duration of disease was longer in the imatinib group compared to the non-imatinib group (mean of 1287 days vs 458 days, P ¼ 0.002). This resulted in a higher proportion of CML patients transplanted in an advanced phase of disease in the imatinib group (62%) compared to the non-imatinib group (9%). All these factors contributed to the statistically significant difference in the proportion of CML patients with Gratwohl scores of 3 or higher (100% in the imatinib group and 32% in the non-imatinib group, Po0.001). Each of the ALL patients who did not receive imatinib were transplanted in complete haematological remission, while none of the imatinib patients were transplanted in complete remission (P ¼ 0.03). Of 30 imatinib patients, 26 (87%) had all LFTs within the normal range, and four (13%) had one LFT increased (two patients elevated FALK and two patients elevated ALAT) prior to the start of conditioning. All patients with increased LFT received imatinib for fewer than 200 days. There were no patients with more than one elevated liver function test within the imatinib group. Of 48 non-imatinib patients, 43 (89%) had all LFTs within the normal range. Two patients had one elevated LFT (one patient ALAT, another ASPAT), and three patients had two elevated LFTs (two patients bilirubin and FALK, one patient ALAT and ASPAT). Viral disease was not documented in any of the patients with elevated aminotransferases.
Engraftment
Two patients from the imatinib group and two patients from the non-imatinib group failed to reach a sustained neutrophil count of more than 500/ml before dying at days 12 and 29 (imatinib group) and 28 and 29 (non-imatinib group) after transplantation. These patients and two others from both the imatnib and non-imatinib group failed to reach a sustained platelet count of more than 50 000/ml. These four other patients died at days 64 and 402 (imatinib group) and 80 and 82 (non-imatinib group). Neutrophil and platelet engraftment is shown in Table 2 . After adjusting for Gratwohl scale among patients with a sustained neutrophil engraftment, the imatinib patients took, on average, 3.84 fewer days to reach ANC 4500 compared to the non-imatinib individuals, although the difference was not statistically significant (P ¼ 0.18). Similarly, among patients who achieved a platelet count 450 000, the imatinib patients did so 6.90 days faster than the non-imatinib patients after adjusting for Gratwohl scale (P ¼ 0.22). Two patients received imatinib during the conditioning regimen. One of them died on day 12 due to infection, and the other achieved neutrophil engraftment and an unsupported platelet count 450 000 on day 15.
There was no statistically significant difference in time to engraftment among patients who received imatinib for less than 200 days compared to more than 200 days, but the patients who were treated for the shorter duration engrafted more rapidly (4.0 days faster to ANC 4500, P ¼ 0.29; 11.8 days faster to 450 000 platelets, P ¼ 0.11).
Liver toxicity
The proportion of patients with bilirubin, FALK, ALT and AST increased 1.5 times the upper normal limit within 100 days after transplantation was similar among imatinib and non-imatinib patients (Table 3) . After adjusting for Gratwohl scale, the hazard of reaching such a level was less in the imatinib group compared to the non-imatinib group, but none of the differences were statistically significant. Similarly, the duration of elevated values, after adjusting for Gratwohl scale, was less in the imatinib group compared to the non-imatinib group (with the exception of AST), but none of the differences were statistically significant ( Table 4 ). The mean peak value of bilirubin was 3.8 and 2.3 mg/dl among imatinib and non-imatinib patients, respectively. After adjusting for Gratwohl scale, the estimated difference was 0.73 mg/dl higher in the imatinib group, but not statistically significantly different (P ¼ 0.48). Since total serum bilirubin level has been shown to be predictive of survival after myeloablative HSCT, 22 we also compared the odds of severe hyperbilirubinaemia (X4 mg/dl) within 100 days. There were seven (23.3%) patients with severe hyperbilirubinaemia in the imatinib group and six patients (12.5%) in the non-imatinib group. The adjusted (for Gratwohl scale) odds of developing Table 2 The neutrophil (ANC 4500 ml) and platelet engraftment among imatinib and non-imatinib patients receiving bone marrow or peripheral blood as a source of stem cells 
Table 3
The proportion of patients and the hazard of LFT increased more than 1.5 times the upper normal limit within 100 days after transplantation among imatinib and non-imatinib patients severe hyperbilirubinaemia after transplantation among imatinib patients was similar to that among non-imatinib (OR 1.12 (95% CI, 0.26-4.78) P ¼ 0.88). The only measure of liver toxicity that was suggestively different among the shorter-duration compared to the longer-duration imatinib patients was duration of elevated AST, where the patients who received imatinib for 1-200 days had an adjusted average of 9.7 more elevated days (P ¼ 0.05). Altogether 30% of imatinib and 35% of non-imatinib patients developed grade 3-4 liver toxicity according to the NCI criteria ( Table 5) . Few of the patients with an increased bilirubin met all the clinical criteria of SOS, which was diagnosed in only three (10%) imatinib patients and in one (2%) non-imatinib patient at a median of 10 days (range 5-13 days) after transplantation. In all patients SOS resolved completely by day 100.
Kidney toxicity
The proportion of patients with creatinine elevation graded according to the NCI criteria is shown in Table 5 . Increased creatinine level of more than 1.5 times the upper normal limit (X2 mg%) within 100 days after transplantation was documented in five (17%) imatinib patients and seven (15%) non-imatinib patients. The adjusted hazard of having such a creatinine level was statistically significantly higher in the imatinib group (HR 4.09 (95%CI 1.25-13.34) P ¼ 0.02). The estimated difference in the number of days with elevated creatinine among imatinib and non-imatinib patients, adjusted for the Gratwohl scale and survival within 100 days, was suggestively higher among imatinib patients (7.8 days, P ¼ 0.08). The adjusted number of days with elevated creatinine among patients who received imatinib for 1-200 days was longer than that among patients who received imatinib for 4200 days (13.0 days, P ¼ 0.03).
Acute GVHD
One patient in the imatinib group was not graded for aGVHD. In all, 14 of the remaining 29 (48%) developed grades II-IV aGVHD compared with 20 of 48 (42%) non-imatinib patients. Five of 29 (17%) vs nine of 48 (19%) developed grades III-IV GVHD. The unadjusted odds of grades II-IV aGVHD among patients who received imatinib were 1.31 times that among patients who did not receive imatinib (95% CI, 0.52-3.30, P ¼ 0.57). The odds ratio adjusted for the Gratwohl scale was 0.86 (0.28-2.46, P ¼ 0.78). The adjusted odds of GVHD were higher among the shorter-duration imatinib patients compared to the longer-duration patients (OR ¼ 3.6), but the difference was not statistically significant (P ¼ 0.12).
Chronic GVHD
Clinical extensive chronic GVHD developed in 10 patients in the imatinib group compared to 12 non-imatinib patients at a median of 156 (76-861) and 157 (98-123) days after transplant, respectively. The adjusted hazard ratio of chronic GVHD was 0.59 (95% CI, 0.21-1.65, P ¼ 0.31).
The adjusted hazard of chronic GVHD among patients who received imatinib for 1-200 days was higher than that among patients who received imatinib for 4200 days (HR ¼ 2.5), but the difference was not statistically significant.
Survival
Five of 30 (17%) imatinib patients died prior to day 100 compared to six of 48 (13%) non-imatinib patients ( Figure 1 ). After adjusting for Gratwohl scale, the odds of dying by day 100 were less in the imatinib group compared to the non-imatinib group, but not statistically significantly so (OR ¼ 0.65 (95% CI 0.13-3.22), P ¼ 0.60). Day-100 mortality was lower among patients who received imatinib for fewer than 200 days compared to those who received imatinib for 4200 days, but the difference was not statistically significant (OR ¼ 0.4, P ¼ 0.44). Overall, 14 (47%) imatinib patients and 18 (38%) non-imatinib patients have died by last contact. Among the 16 imatinib Table 5 The proportion of patients among imatinib and nonimatinib group developing grade 0-4 liver and kidney toxicity according to the NCI common terminology criteria of adverse events Non-imatinib (n=48) Figure 1 The probability of day-100 mortality in imatinib (solid line) and non-imatinib (dashed line) patients.
survivors, the median follow-up is 617 days (range of 435-1033 days), and the median follow-up among the 30 survivors in the non-imatinib group is 1068 days (range 381-3385 days). Among the deaths that occurred in the imatinib group before day 100, two occurred due to infectious complications, two from aGVHD and two from disease relapse (ALL and CML). After day 100, three imatinib patients died from extensive chronic GVHD; one from pulmonary aspergillosis, one from myocardial infarction and one from indefinite cause. One CML patient died from progression of colon cancer detected a year after transplantation. He remained in complete cytogenetic and molecular remission. Three patients (two with ALL and one with CML) died from disease relapse. Among the deaths before day 100 in the non-imatinib group, one occurred from infectious complications, four due to aGVHD and one from haemorrhagic cystitis. After day 100, six patients died from extensive chronic GVHD, two patients from infection, one from cerebral bleeding. Three patients (one ALL and two CML) died from disease relapse.
Disease response in imatinib patients ALL. All four patients with ALL relapsed, of whom three died due to disease progression. One patient who relapsed 1 year after transplant received chemotherapy and achieved complete haematological response, which has been maintained for 5 months on imatinib. Chimerism studies showed 100% of donor cells.
CML. Three patients relapsed. Two of them died due to disease progression, one is alive in chronic phase and is receiving imatinib for more than a year after transplantation without achieving a cytogenetic response.
Discussion
In contrast to an earlier report, 23 we did not find any evidence that imatinib administered prior to myeloablative HSCT increases acute transplant-related toxicities. A similar observation, but based on much smaller number of patients, was published by Shimoni et al 24 and more recently by Oehler et al. 25 The observed outcomes in our population were generally worse among the imatinib patients, but these patients had, on average, much worse characteristics as evidenced by the higher Gratwohl scale in this group compared to that in the non-imatinib group. Therefore, if there were no real positive or negative effects of imatinib on the end points that we examined, one would expect the imatinib group to have a worse outcome.
Impairment of donor cell engraftment due to imatinib was evaluated as a potential complication because of the myelosuppression that has been observed in patients treated with BCR/ABL-positive leukaemias 26 and in patients with gastrointestinal stromal tumours., 27 Imatinib was therefore stopped at the start of conditioning in almost all patients studied in the current report. However, there are at least two factors that could have rendered this approach questionable. First, the main biologically active metabolite of imatinib, N-desmethyl CGP 74588, with a biological half-life four-fold longer than imatinib (89.65 vs 16.9 h), 28 could be present at the time of donor-cell infusion. Second, the conditioning regimen and concomitant supportive treatment could change the pharmacokinetic properties of imatinib and its metabolite N-desmethyl CGP 74588, possibly extending their half-lives. 29 Our results are in agreement with a previous report indicating that use of imatinib when stopped before allo-HSCT does not interfere with donor engraftment. 24 The successful engraftment of one patient receiving imatinib during conditioning raises the possibility that continued administration of imatinib in the course of HSCT may be feasible. Studies in lethally irradiated mice transplanted from syngeneic donors also showed that continuous therapy with imatinib had no significant influence on haematopoietic recovery. 30 This is consistent with data obtained from nontransplant patients indicating that imatinib did not severely affect normal haematopoiesis. 27 Moreover, in vitro data showed that therapeutic doses of imatinib inhibited normal progenitor colony formation by only 10-20%. 31, 32 Preliminary data from a patient treated with a nonmyeloablative stem cell transplant and receiving imatinib concomitantly is also consistent with this notion. 33 Liver toxicity is a common and potentially fatal complication after myeloablative conditioning therapy. Previous studies showed that transplants recipients with pre-existing liver injury had an increased risk of liver complications and death. 21 Imatinib is known to induce liver toxicity resulting in a mild increase in transaminases and occasionally increases in bilirubin. The aetiology of the hepatotoxicity remains unclear, though liver biopsy suggests a typical drug-induced hypersensitivity.
14 In general, liver impairment occurs rather early during imatinib therapy, resolving with drug withdrawal and allowing imatinib to be restarted in most cases. 4, 13 In our study we did not observe statistically significant augmented liver toxicity in patients treated with imatinib prior to HSCT, at least after considering the differences in Gratwohl scale between the two groups. The frequency of bilirubin level greater than 4 mg/dl by 100 days was similar in both groups after adjusting for the differences in Gratwohl scale but less than in a large cohort of patient reported from Seattle. 22 This discrepancy could be not only due to the much smaller number of patients studied here but could also result from the difference in the type of conditioning regimen used and patients transplanted. For the data currently reported, most of the patients received busulfan, whereas TBI-based conditioning regimens were used for patients reported from Seattle. Increased incidence of hepatic toxicity after transplantation has been observed by Shimoni et al 24 in patients receiving a short course of imatinib before HSCT. However, it is not clear if the high occurrence of hepatic dysfunction in these patients was indeed caused by imatinib since duration of imatinib treatment was rather short (median 30 days) and most of these patients received chemotherapy and intensive conditioning, which obviously caused liver impairment. The relatively high incidence of VOD in CML patients in blast crisis (seven of 23) after allogeneic HSCT is consistent with this notion. 34 Late onset of hepatic toxicity has been reported, 13 occurring 293-541 days after the start of imatinib, suggesting that the deleterious effect of imatinib on liver function may increase with time. Our analysis is limited by the fact that most of our patients received imatinib for less than a year and in none of them was imatinib-related liver injury documented before HSCT. Longer treatment or higher doses of imatinib could still affect liver function in transplant recipients.
The observation of increased renal toxicity among imatinib patients is difficult to explain and may simply reflect the worse characteristics of this group. However, this was not caused by a prior antifungal therapy since only one patient with elevated creatinine received an intensive induction treatment before transplantation.
We did not observe any cardiac dysfunction in the current study, unlike an earlier report. 35 One sudden death most likely caused by cardiac arrest 647 days after transplantation would be difficult to link with prior imatinib due to the long interval from the end of imatinib therapy to that episode.
The current study did not aim to assess the impact of pretransplant imatinib therapy on disease response. That said, there was no evidence suggesting that imatinib treatment improved the disease response, particularly in high-risk patients. Three ALL transplant survivors relapsed and only one achieved haematological response after chemotherapy, the latter patient maintained for 5 months on imatinib. Interestingly, this patient had only a partial haematological response to imatinib before transplantation. For patients with CML the estimated overall survival at 1 year of 65% is reasonably good, taking into account that more than half the patients were in advanced phase of disease. While encouraging, the current outcome is not obviously superior to that observed by others in such patients not treated with imatinib. 34, 36 We hypothesize that a potential adverse effect of imatinib on transplant-related toxicity, if it were to occur, should be observed relatively early (by day 100) rather than later after transplantation. Similar day-100 survival among patients receiving imatinib and those not receiving imatinib prior to HSCT suggests that imatinib use does not increase the incidence of transplant-related toxicities. The control group of patients that we had at our disposal was less than optimal as evidenced by the significant difference in average Gratwohl score between the two groups. Nonetheless, after adjusting for this difference there was no suggestion that transplant-related toxicity was worse among patients who received imatinib compared to those who did not. Longer duration (4200 days) of imatinib therapy also appeared not to affect HSCT outcomes. However, given the relatively small number of patients currently reported and the differences in risk factors between the two groups, our conclusions must be interpreted with caution.
